Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer

Abstract Background Oxaliplatin is one of the most commonly used chemotherapeutic agent for the treatment of various cancers, including gastric cancer. It has, however, a narrow therapeutic index due to its toxicity and the occurrence of drug resistance. Hence, it is of great significance to develop...

Descrición completa

Detalles Bibliográficos

Principais autores:	Haiyong Zhang, Jing Wu, Jinqiu Yuan, Huafu Li, Yawei Zhang, Wang Wu, Wei Chen, Chunming Wang, Sijun Meng, Songyao Chen, Mingyu Huo, Yulong He, Changhua Zhang
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2021-08-01
Series:	Journal of Experimental & Clinical Cancer Research
Assuntos:	Tumor growth inhibition Thioredoxin reductase 1 Reactive oxygen species Ethaselen Oxaliplatin Organoids
Acceso en liña:	https://doi.org/10.1186/s13046-021-02052-z
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!